Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
JAMA ; 329(16): 1356-1366, 2023 04 25.
Artigo em Inglês | MEDLINE | ID: mdl-37060545

RESUMO

Importance: The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown. Objective: To determine the efficacy of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, in adults at high risk for CDI recurrence. The primary objective was to determine the recommended VE303 dosing for a phase 3 trial. Design, Setting, and Participants: Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. The study included 79 participants aged 18 years or older who were diagnosed with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence (defined as aged ≥75 years or ≥65 years with ≥1 risk factors: creatinine clearance <60 mL/min/1.73 m2, proton pump inhibitor use, remote [>6 months earlier] CDI history). Interventions: Participants were randomly assigned to high-dose VE303 (8.0 × 109 colony-forming units [CFUs]) (n = 30), low-dose VE303 (1.6 × 109 CFUs) (n = 27), or placebo capsules (n = 22) orally once daily for 14 days. Main Outcomes and Measures: The primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. The primary efficacy end point was analyzed in 3 prespecified analyses, using successively broader definitions for an on-study CDI recurrence: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea consistent with CDI plus a toxin-positive, polymerase chain reaction-positive, or toxigenic culture-positive stool sample; and (3) diarrhea consistent with CDI plus laboratory confirmation or (in the absence of a stool sample) treatment with a CDI-targeted antibiotic. Results: Baseline characteristics were similar across the high-dose VE303 (n = 29; 1 additional participant excluded from efficacy analysis), low-dose VE303 (n = 27), and placebo (n = 22) groups. The participants' median age was 63.5 years (range, 24-96); 70.5% were female; and 1.3% were Asian, 1.3% Black, 2.6% Hispanic, and 96.2% White. CDI recurrence rates through week 8 (using the efficacy analysis 3 definition) were 13.8% (4/29) for high-dose VE303, 37.0% (10/27) for low-dose VE303, and 45.5% (10/22) for placebo (P = .006, high-dose VE303 vs placebo). Conclusions and Relevance: Among adults with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings. Trial Registration: ClinicalTrials.gov Identifier: NCT03788434.


Assuntos
Clostridioides difficile , Infecções por Clostridium , Probióticos , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Infecções por Clostridium/complicações , Infecções por Clostridium/microbiologia , Infecções por Clostridium/prevenção & controle , Infecções por Clostridium/terapia , Diarreia/etiologia , Diarreia/microbiologia , Diarreia/prevenção & controle , Diarreia/terapia , Fezes/química , Fezes/microbiologia , Microbioma Gastrointestinal , Probióticos/administração & dosagem , Probióticos/uso terapêutico , Recidiva , Reinfecção/prevenção & controle , Simbiose , Resultado do Tratamento , Método Duplo-Cego , Toxinas Bacterianas/análise , Adulto Jovem , Idoso , Idoso de 80 Anos ou mais
2.
Blood Cells Mol Dis ; 39(1): 115-8, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17391996

RESUMO

OBJECTIVES: To evaluate pharmacokinetics of Gene-Activated human glucocerebrosidase (GA-GCB), a novel enzyme replacement therapy, in patients with type 1 Gaucher disease. STUDY DESIGN: Open-label study of GA-GCB, administered as a 1-h intravenous (IV) infusion every other week was evaluated. The first three patients sequentially received one infusion each at 15 U/kg, 30 U/kg, and 60 U/kg at 2-week intervals and then continued with 60 U/kg/infusion every other week; subsequently nine more patients received GA-GCB at 60 U/kg/infusion every other week. Each patient received 20 infusions (40 weeks). Pharmacokinetic (PK) parameters reported are from blood samples collected at Weeks 1, 3, and 5 for dose-escalated patients and at Week 1 from the other nine patients. RESULTS: GA-GCB was rapidly cleared from the circulation and followed first-order elimination kinetics in the 12 patients who received IV infusions. Maximum serum concentration (C(max)) coincided with the end of the 1-h infusion. Both C(max) and area under the curve (AUC) were linearly proportional to dose from 15 U/kg to 60 U/kg. Elimination half-life was independent of dose; mean elimination half-life at 60 U/kg was approximately 10 min (range: 4-15 min). Mean serum clearance was 13 ml/min/kg (range: 9-20 ml/min/kg) and V(ss) (apparent volume of distribution) was approximately 18% body weight (range: 11-27% body weight). CONCLUSIONS: GA-GCB demonstrated linear PK parameters over clinically relevant doses (15 U/kg-60 U/kg) indicating that the dose of IV-administered GA-GCB to target tissues should also be linearly proportional to dose.


Assuntos
Doença de Gaucher/sangue , Doença de Gaucher/tratamento farmacológico , Glucosilceramidase/administração & dosagem , Glucosilceramidase/farmacocinética , Adolescente , Adulto , Estudos de Coortes , Relação Dose-Resposta a Droga , Feminino , Humanos , Injeções Intravenosas , Masculino , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA